DESTINY-Breast06
DESTINY-Breast06: Phase III Trial of Trastuzumab Deruxtecan vs Chemotherapy in Previously Treated HR+/HER2-Low or Ultralow MBC

Released: June 05, 2024

Expiration: June 04, 2025

Activity

Progress
1
Course Completed